Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early Triple-negative Breast Cancer (TNBC). An Open-label Randomized Two-cohort Phase 2 Clinical Trial. INVINCIBLE-4-SAKK

About 10-20% of all individuals with breast cancer have a so-called triple-negative tumor (TNBC). This type of breast cancer has a particularly unfavorable course and a higher mortality rate compared to other forms of breast cancer. Research studies show that it is important for individuals with TNBC to achieve a so-called pathologic complete response (pCR) to treatment. In the phase II study SAKK 66/22, it is being investigated whether the administration of the drug INT230-6 before surgery for breast cancer can increase the rate of pCR in the tumor and affected lymph nodes. The tolerability of INT230-6 as well as other factors such as response to treatment and the possibility of breast-conserving surgery are also being examined.

开始日期2024-10-24

申办/合作机构-

NCT06263231

/ Active, not recruiting临床3期

A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adults With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas (INVINCIBLE-3)

To compare Overall Survival (OS) for INT230-6 vs United States (US) Standard of Care (SOC) in participants with unresectable or metastatic liposarcoma, undifferentiated pleomorphic sarcoma or leiomyosarcoma who have disease progression prior to study enrollment following no more than 2 standard therapies, which must have included an anthracycline-based regimen, unless contraindicated, and then a maximum of 1 additional regimen.

开始日期2024-06-28

申办/合作机构

Intensity Therapeutics, Inc.

[+1]

NCT04781725

/ Unknown status临床2期IIT

A Phase II Randomized Window of Opportunity Trial Evaluating Clinical and Biological Effects of Intratumoral INT230-6 in Early Stage Breast Cancer: The INVINCIBLE Trial

This is a phase II, randomized, multi-center, parallel design, window of opportunity trial evaluating intratumoral INT230-6 in up to 90 patients with early stage breast cancer. In a 2:1 randomization, patients on the treatment arm will receive intratumoral INT230-6 injections prior to breast surgery.

开始日期2021-03-25

申办/合作机构

Ottawa Hospital Research Institute

[+2]

100 项与顺铂/长春碱/SHAO 相关的临床结果

登录后查看更多信息

100 项与顺铂/长春碱/SHAO 相关的转化医学

登录后查看更多信息

100 项与顺铂/长春碱/SHAO 相关的专利（医药）

登录后查看更多信息

项与顺铂/长春碱/SHAO 相关的文献（医药）

2019-10-03·Oncoimmunology2区 · 医学

Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory

2区 · 医学

ArticleOA

作者: Bender, Lewis H. ; Jones, Jennifer C. ; Pasquet, Lise ; Tiwary, Shweta ; Xia, Zheng ; Bloom, Anja C. ; Berzofsky, Jay A. ; Terabe, Masaki ; Walters, Ian ; Morales-Kastresana, Aizea ; Clark, Katharine ; Jiang, Tianbo

The benefits of anti-cancer agents extend beyond direct tumor killing. One aspect of cell death is the potential to release antigens that initiate adaptive immune responses. Here, a diffusion enhanced formulation, INT230-6, containing potent anti-cancer cytotoxic agents, was administered intratumorally into large (approx. 300mm³) subcutaneous murine Colon26 tumors. Treatment resulted in regression from baseline in 100% of the tumors and complete response in up to 90%. CD8⁺ or CD8⁺/CD4⁺ T cell double-depletion at treatment onset prevented complete responses, indicating a critical role of T cells in promoting complete tumor regression. Mice with complete response were protected from subcutaneous and intravenous re-challenge of Colon26 cells in a CD4⁺/CD8⁺ dependent manner. Thus, immunological T cell memory was induced by INT230-6. Colon26 tumors express the endogenous retroviral protein gp70 containing the CD8⁺ T-cell AH-1 epitope. AH-1-specific CD8⁺ T cells were detected in peripheral blood of tumor-bearing mice and their frequency increased 14 days after treatment onset. AH-1-specific CD8⁺ T cells were also significantly enriched in tumors of untreated mice. These cells had an activated phenotype and highly expressed Programmed cell-death protein-1 (PD-1) but did not lead to tumor regression. CD8⁺ T cell tumor infiltrate also increased 11 days after treatment. INT230-6 synergized with checkpoint blockade, inducing a complete remission of the primary tumors and shrinking of untreated contralateral tumors, which demonstrates not only a local but also systemic immunological effect of the combined therapy. Similar T-cell dependent inhibition of tumor growth was also found in an orthotopic 4T1 breast cancer model.

2018-10-01·ANNALS OF ONCOLOGY

Phase I/II evaluation of intratumoral INT230-6 for the treatment of solid tumors

Article

作者: Bender, L ; Olszanski, A J ; Siu, L L ; Walters, I B ; Azad, N ; El-Khoeuiry, A ; Kamen, L

2017-09-01·Nature medicine1区 · 医学

Uncovering cancer: How enlisting T cells can boost the power of immunotherapy

1区 · 医学

Article

作者: Keener, Amanda B.

Many companies are now using immunogenic cell death as the basis for new approaches to increase the success of checkpoint inhibitors against tumors that tend to remain hidden from T cells.Intensity Therapeutics, a biotech company based in Westport, Connecticut, has developed a formulation called INT230-6, which pairs two common chemotherapies, vinblastine and cisplatin, with a mol. that enhances the drugs′ ability to penetrate cell membranes.Intensity has been working with vaccine immunologists at the US National Cancer Institute (NCI), and has tested the drug against mouse pancreatic, colon, and breast cancer tumors grown under the skin of mice.At the annual meeting of the American Association for Cancer Research (AACR) in Apr., NCI scientists reported that daily injections of INT230-6 into colon cancer tumors grown under the skin of mice for five days resulted in a surge of CD8 T cells into the tumors.When the NCI researchers combined INT230-6 with anti-PD-1 therapy, the tumors were untraceable in five of the nine treated animals."These mice have about two weeks left to live when we start the treatment, and 55% get cured and never get cancer again," says Lew Bender, Intensity′s CEO and founder.By contrast, there were no changes to the tumors of any of the mice, which were immunocompetent, when they were treated with checkpoint inhibitors alone.The company plans to test its drugs in combination with an anti-PD-1 antibody in its ongoing phase 1/2 trial, in which 60 patients with various forms of cancer will receive injections into their tumors once a month for five months.Anja Bloom, an immunologist at the NCI who headed up these experiments, says that she is now working to define the mechanisms that entice CD8 T cells into INT230-6-treated tumors.So far, she has found that the drug attracts to the tumors innate immune cells called dendritic cells, which digest and display pieces of dying cancer cells to train T cells to recognize cancer as something foreign.It′s not clear yet, however, whether the drug induces the release of DAMPs.Other groups in the field are also focused on understanding how cell death activates T cells and a broader immune response.In the late 2000s, a team headed by Guido Kroemer and Laurence Zitvogel at the Gustave Roussy Institute of Oncol. near Paris began to define what makes a dying tumor cell immunogenic.In 2007, they reported that a chemotherapy that caused dying cancer cells in culture to move a protein called calreticulin from the cytoplasm to the cell membrane allowed those cells to trigger an antitumor immune response once injected into mice.That immune response also protected the mice from developing tumors after researchers later injected live cancer cells.They went on to add high-mobility-group box 1 protein (HMGB1)-which normally acts in the nucleus to regulate gene transcription-and the energy-containing mol. ATP (ATP) to the list of DAMPs released by some dying cells.Chemotherapy is not the only way to induce immunogenic cell death.For example, Pittet is now working with the Norwegian company Lytix Biopharma to develop a peptide that breaks apart cancer cells and causes them to release DAMPs that attract T cells.Meanwhile, dozens of trials around the world are testing whether they can improve treatment by combining radiation with either ipilimumab or nivolumab.Laurent Levy, CEO and founder of the Paris-based company Nanobiotix, says that things really got exciting for his company about two years ago, when it started taking note of what its lead candidate, NBTXR3, does to tumor immunol.When cancer cells treated with NBTXR3 are hit with radiation, Levy says, the nanoparticles produce reactive atoms called free radicals.These mols. in turn amplify damage to the tumor cells, causing them to release more DAMPs and set off an antitumor immune response."Instead of using biol. or chem. to kill cancer, we use physics," Levy says.This year, at an immunotherapy workshop co-sponsored by the NCI, the Society for Immunotherapy of Cancer, and the American Society for Radiation Oncol., Levy and his colleagues reported preliminary results from a phase 2/3 trial to treat individuals with soft-tissue sarcoma.Their findings showed that combining NBTXR3 treatment with radiation increased the average number of CD8 T cells in eight patient tumors.Tumors from another set of six people who received only radiation, without NBTXR3, on the other hand, displayed no increase in CD8 T cells.The trial, which is still ongoing, was not designed to test the role of the immune response in overall survival, but Levy says that the company is taking advantage of biopsy samples from the trial to explore how the nanoparticles alter immune cells and gene expression in treated tumors.Nanobiotix is now planning a trial of its product in combination with checkpoint inhibitors."Potentially, we can apply this across oncol.," Levy says.Although researchers are relying on the presence of CD8 T cells in a tumor to determine whether the tumor may be more likely to respond to checkpoint-inhibitor therapy, Adi Diab, an oncologist at MD Anderson Cancer Center in Houston, cautions against using these T cells as tell-tale markers."In reality, we do not have absolute predictors for immunotherapy [response]," Diab says.

项与顺铂/长春碱/SHAO 相关的新闻（医药）

2025-09-10

·PRNewswire

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

临床结果免疫疗法

2025-09-10

·ir.intensitytherapeutics.com

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patient receives two doses of INT230-6 eight days apart, followed by the standard of care immunochemotherapy ("SOC") Safety looks favorable in Cohort A Some INT230-6 patients begin to show localized skin irritation, and new patient enrollment has been paused to implement modifications to resolve the issue Patients being treated with INT230-6 continue to show significant necrosis after two doses of INT230-6 and prior to the initiation of the SOC, as shown in the photos below of a single patient's breast tumor scans SHELTON, Conn., Sept. 10, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today provided an update on the INVINCIBLE-4 trial. A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patient receives two doses of INT230-6 eight days apart, followed by the SOC. To date, there has been favorable safety in cohort A. However, some patients in Cohort A experienced localized skin irritation near the tumor. As a result, new patient enrollment has been paused to evaluate the data collected and to implement necessary adjustments prior to reopening accrual. "While efficacy of INT230-6 is quite promising, and we are excited by the early radiological and pathological results, an essential aspect of any treatment for breast cancer patients is to have a good cosmetic result post-surgery," said Ursina Zürrer, M.D. Chief Physician for Genetic Counseling, Department of Medical Oncology and Hematology, Cantonal Hospital Winterthur, Switzerland, and the Coordinating Investigator for the INVINCIBLE-4 Study. "We believe that the INT230-6 has the potential to make a positive impact on patients with triple-negative breast cancer from a safety and efficacy perspective. We expect to reinitiate the enrollment with a modified INT230-6 dosing regimen as soon as possible. The pause was a decision made with Intensity and not a directive from any regulatory agency." "As was seen in our prior studies, tumor scans indicate high levels of drug absorption and significant tumor necrosis with evidence of immune activation before the initiation of the standard of care therapy, and we are excited that the first patient evaluated who received our drug had a pCR," said Lewis H. Bender, Intensity's President and CEO. "We plan to complete a data evaluation to determine the cause of the skin irritation and implement changes needed to eliminate or reduce the issue. Our objective is to reinitiate enrollment and complete the study as soon as possible. Intensity's ultimate goal is to provide patients with a new product that offers presurgical triple-negative breast cancer patients improved safety and a greater likelihood of having a pathological complete response, while also providing a good appearance post-surgery." About INT230-6 INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform. The drug consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule ("SHAO") that conjugates non-covalently to the two payload drugs and facilitates the dispersion of the potent cytotoxic drugs throughout tumors, allowing the active agents to diffuse into cancer cells. These agents remain in the tumor, resulting in a favorable safety profile. In addition to local disease control and direct tumor killing, INT230-6 causes a release of a bolus of neoantigens specific to the malignancy, leading to immune system engagement and systemic anti-tumor effects. Importantly, these effects are mediated without immunosuppression, which often occurs with systemic chemotherapy. About the INVINCIBLE-4 Study The INVINCIBLE-4 study is a Phase 2 non-comparative, hypothesis-driven randomized open-label, two-cohort multicenter study to analyze the clinical activity, safety, and tolerability of INT230-6 given before administration of the standard of care immunochemotherapy ("SOC") treatment in patients with early-stage, operable triple-negative breast cancer and SOC alone. The primary endpoint is the pathological complete response rate for the combination and the SOC alone. pCR is the absence of cancer at the time of surgery in the tumor and nodes. pCR is an FDA accelerated approval endpoint. Clinical evidence is strong that the risk of a patient's cancer returning is significantly reduced when there is a pCR at the time of surgery. The Swiss Medic and the European Medicines Agency authorized the initiation of the INVINCIBLE-4 Study in Switzerland and France. The SCI led study is also being done in collaboration with Unicancer (UCBG), the French referent cooperative group in breast cancer accredited by the French National Cancer Institute. The expected total enrollment is up to 54 patients. About Intensity Therapeutics Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor's dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies and enrolled over 200 patients using INT230-6: a Phase 1/2 dose escalation study in metastatic cancers including sarcomas (NCT03058289), and a Phase 2 randomized control clinical trial in locally advanced breast cancer (the "INVINCIBLE-2 Study") (NCT04781725) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the "INVINCIBLE-3 Study") (NCT06263231), testing INT230-6 as second or third-line monotherapy compared to the standard of care ("SOC") with overall survival as an endpoint. Intensity also initiated a Phase 2 study in collaboration with The Swiss Group for Clinical Cancer Research, SAKK (the "INVINCIBLE-4 Study") (NCT06358573) as part of a Phase 2/3 program evaluating INT230-6 followed by the SOC immunochemotherapy and the SOC alone for patients with presurgical triple-negative breast cancer. Pathological complete response ("pCR") is the endpoint. For more information about Intensity, including publications, papers, and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com. Forward-Looking Statements Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, the potential efficacy and safety of INT230-6 for patients with triple-negative breast cancer, statements relating to the Company's expected future plans, cash runway, development activities, projected milestones, business activities or results. When or if used in this communication, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company's research to generate and advance additional product candidates; results observed from preliminary data are not necessarily indicative of final results and one or more of the clinical outcomes may materially change following more comprehensive reviews of the data and as more patient data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations; the risk that product candidates that appear promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials; the implementation of the Company's business model, strategic plans for the Company's business, product candidates and technology; commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of the Company's system; the Company's competitive position; the Company's intellectual property position; developments and projections relating to the Company's competitors and its industry; the Company's ability to maintain and establish collaborations or obtain additional funding; expectations related to the use of cash and cash equivalents and investments; our potential inability to satisfy the Nasdaq Capital Market's requirements for continued listing and be subject to delisting; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other risks described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in the Company's subsequent SEC ﬁlings, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law. Investor Relations Contact: Justin Kulik justin@coreir.com (558) 230-6401 Media Contact: Jules Abraham CORE IR julesa@coreir.com View original content to download multimedia:https://www.prnewswire.com/news-releases/intensity-therapeutics-reports-invincible-4-presurgical-triple-negative-breast-cancer-study-update-302551851.html SOURCE Intensity Therapeutics Inc. Released September 10, 2025

临床2期免疫疗法临床结果临床3期加速审批

2025-08-12

·ir.intensitytherapeutics.com

Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

SHELTON, Conn., Aug. 12, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces that the Company received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Staff has determined that the Company has regained compliance with Nasdaq's minimum Stockholders' Equity Requirement. On August 7, 2025, the Company filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 stating that based on the Company's balances in cash and cash equivalents as of June 30, 2025, plus the cash raised through the end of July 2025, the Company believed that it had at least $2,500,000 in stockholders' equity, as required pursuant to the Stockholders' Equity Requirement. On August 8, 2025, the Staff determined that the Company had regained compliance with the Nasdaq's minimum Stockholders' Equity Requirement. "We are pleased with regaining compliance with the minimum Stockholders' Equity Requirement based on our positive fundraising efforts through the end of July 2025," said Lewis H. Bender, President and CEO of Intensity. "Based on the cash raised through July 2025, we now project to have sufficient cash to fund our current operating plan into the second half of 2026." About INT230-6 INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform. The drug consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule ("SHAO") that facilitates the dispersion of potent cytotoxic drugs throughout tumors, allowing the active agents to diffuse into cancer cells. These agents remain in the tumor, resulting in a favorable safety profile. In addition to local disease control and direct tumor killing, INT230-6 causes a release of a bolus of neoantigens specific to the malignancy, leading to immune system engagement and systemic anti-tumor effects. Importantly, these effects are mediated without immunosuppression, which often occurs with systemic chemotherapy. About Intensity Therapeutics Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor's dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies and enrolled over 200 patients using INT230-6: a Phase 1/2 dose escalation study in metastatic cancers including sarcomas (NCT03058289), and a Phase 2 randomized control clinical trial in locally advanced breast cancer (the "INVINCIBLE-2 Study") (NCT04781725) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the "INVINCIBLE-3 Study") (NCT06263231), testing INT230-6 as second or third-line monotherapy compared to the standard of care ("SOC") with overall survival as an endpoint. Intensity also initiated a Phase 2 study (the "INVINCIBLE-4 Study") (NCT06358573) in collaboration with the Swiss Cancer Group, formerly the Swiss Group for Clinical Cancer Research, SAKK, as part of a Phase 2/3 program evaluating INT230-6 followed by the SOC immunochemotherapy and the SOC alone for patients with presurgical triple-negative breast cancer. Pathological complete response ("pCR") is the endpoint. For more information about Intensity, including publications, papers, and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com. Forward-Looking Statements Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company's expected future plans, cash runway, development activities, projected milestones, business activities or results. When or if used in this communication, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company's research to generate and advance additional product candidates; the risk that product candidates that appear promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials; the implementation of the Company's business model, strategic plans for the Company's business, product candidates and technology; commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of the Company's system; the Company's competitive position; the Company's intellectual property position; developments and projections relating to the Company's competitors and its industry; the Company's ability to maintain and establish collaborations or obtain additional funding; expectations related to the use of cash and cash equivalents and investments; our potential inability to satisfy the Nasdaq Capital Market's requirements for continued listing and be subject to delisting; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other risks described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in the Company's subsequent SEC ﬁlings, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law. Investor Relations Contact: Justin Kulik Justin@coreir.com CORE IR (516) 222-2560 Media Contact: Jules Abraham CORE IR pr@coreir.com View original content to download multimedia:https://www.prnewswire.com/news-releases/intensity-therapeutics-inc-regains-compliance-with-nasdaqs-minimum-stockholders-equity-requirement-302527488.html SOURCE Intensity Therapeutics Inc. Released August 12, 2025

免疫疗法临床2期临床3期

100 项与顺铂/长春碱/SHAO 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性软组织肉瘤	临床3期	美国	Intensity Therapeutics, Inc.	2024-06-28
转移性软组织肉瘤	临床3期	加拿大	Intensity Therapeutics, Inc.	2024-06-28
转移性软组织肉瘤	临床3期	法国	Intensity Therapeutics, Inc.	2024-06-28
转移性软组织肉瘤	临床3期	德国	Intensity Therapeutics, Inc.	2024-06-28
转移性软组织肉瘤	临床3期	西班牙	Intensity Therapeutics, Inc.	2024-06-28
软组织肉瘤	临床3期	加拿大	AlphaTON Capital Corp.	2023-11-15
三阴性乳腺癌	临床2期	瑞士	-	2024-10-24
早期乳腺癌	临床2期	加拿大	Intensity Therapeutics, Inc.	2021-03-25
胆管癌	临床2期	美国	Intensity Therapeutics, Inc.	2017-02-09
胆管癌	临床2期	加拿大	Intensity Therapeutics, Inc.	2017-02-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03058289 (Company_Website) 人工标引	临床3期	肉瘤	-	INT230-6	鏇淵繭鹹築獵鏇夢夢鏇(襯獵繭鑰膚遞醖鹽淵鏇) = 遞蓋糧範繭夢夢憲構壓廠鏇範壓廠膚築艱鏇鬱 (構淵願願糧襯積夢壓鏇 ) 更多	积极	2025-01-03
				INT230-6 (failing a median of 3 lines of prior therapy)	鏇淵繭鹹築獵鏇夢夢鏇(襯獵繭鑰膚遞醖鹽淵鏇) = 衊鹹糧鏇觸齋餘鏇齋構廠鏇範壓廠膚築艱鏇鬱 (構淵願願糧襯積夢壓鏇 )
NCT03058289 (Corporate Publications) 人工标引	临床1/2期	肉瘤	29	INT230-6	鏇網襯鏇築鏇淵觸夢觸(選壓網艱膚鹹壓築遞網) = 衊廠鬱糧淵鹽積鬱顧製鬱鬱獵膚顧鹽廠顧鹹餘 (窪衊簾範獵觸範鬱襯網 ) 更多	积极	2023-11-02
				INT230-6+ipilimumab	鏇網襯鏇築鏇淵觸夢觸(選壓網艱膚鹹壓築遞網) = 製壓鬱壓觸衊齋齋築遞鬱鬱獵膚顧鹽廠顧鹹餘 (窪衊簾範獵觸範鬱襯網 ) 更多
NCT03058289 (CA184-592, ASCO 12023 \| ASCO 22023) 人工标引	临床1/2期	肉瘤	29	INT230-6	糧窪鬱窪壓獵遞築鑰艱(遞糧構鹹蓋夢衊醖鏇範) = 鹹衊壓壓鏇廠壓範網遞願齋糧淵積獵鏇襯廠齋 (築壓鑰繭壓遞餘願鑰襯 ) 更多	积极	2023-05-31
				Ipilimumab+INT230-6	糧窪鬱窪壓獵遞築鑰艱(遞糧構鹹蓋夢衊醖鏇範) = 鬱範襯壓鬱齋顧觸憲醖願齋糧淵積獵鏇襯廠齋 (築壓鑰繭壓遞餘願鑰襯 ) 更多
NCT04781725 (INVINCIBLE, ASCO 12023 \| ASCO 22023) 人工标引	临床2期	ER阳性乳腺癌 ER Positive	12	INT230-6	衊蓋醖構淵淵鏇衊醖糧(繭餘網餘醖夢積積獵壓) = Significant tumor necrosis was observed in the majority of subjects injected with INT230-6. 繭齋選選獵夢憲鬱築餘 (構膚築壓製範衊範夢構 )	积极	2023-05-31
NCT04781725 (INVINCIBLE Trial, SABCS2023)	临床2期	早期乳腺癌	90	INT230-6	醖艱繭糧憲選壓鬱鹹積(鏇繭簾襯範夢積觸糧鏇) = injection site pain, injection site reaction, nausea/vomiting 壓繭製繭襯築衊艱顧夢 (淵鏇襯廠鏇鏇醖衊廠襯 )	积极	2023-03-01
NCT03058289 (IT-01, Corporate Publications) 人工标引	临床1/2期	实体瘤	88	INT 230-6	繭壓齋醖憲鑰餘廠遞憲(製築衊廠獵夢餘窪願顧) = 壓襯鏇鹹鬱醖餘網範夢鹽顧遞膚遞選製構襯壓 (襯窪選壓選網鏇鹽鹹構 ) 更多	积极	2022-11-11
				INT 230-6+Pembrolizumab	繭壓齋醖憲鑰餘廠遞憲(製築衊廠獵夢餘窪願顧) = 顧糧顧範齋積鑰齋願鑰鹽顧遞膚遞選製構襯壓 (襯窪選壓選網鏇鹽鹹構 ) 更多
NCT04781725 (INVINCIBLE, SITC2022) 人工标引	临床2期	乳腺癌	87	INT 230-6	鏇鏇鑰鹽衊夢淵糧襯餘(顧製廠憲願願醖選築遞) = 鑰醖糧廠築構選網獵繭鹽壓壓鑰衊鹽鹹積築觸 (願艱簾壓構壓夢鑰襯廠 )	积极	2022-11-01
NCT03058289 (Merck KEYNOTE-A10, ASCO2022) 人工标引	临床1/2期	实体瘤	83	INT230-6	壓選鹽淵齋遞築淵壓膚(壓壓鏇願獵糧製構遞願) = none 夢簾襯積願淵鹹壓憲獵 (願蓋憲憲餘遞簾壓選夢 ) 更多	积极	2022-06-02
				INT230-6+pembrolizumab
NCT03058289 (IT-01, ASCO2022) 人工标引	临床1/2期	难治性软组织肉瘤	22	INT230-6	壓鹹範繭鏇夢醖鬱蓋蓋(餘構顧構鑰繭獵壓鹽願) = 願鬱艱顧壓廠選遞範壓選糧選鏇網簾襯鏇構製 (願製廠選簾築顧構鹽製 ) 更多	积极	2022-06-02
				ipilimumab+INT230-6	壓鹹範繭鏇夢醖鬱蓋蓋(餘構顧構鑰繭獵壓鹽願) = 淵願築繭範顧餘選鹹遞選糧選鏇網簾襯鏇構製 (願製廠選簾築顧構鹽製 ) 更多
IT-01 study [KEYNOTE-A10] (SABCS2022)	临床1/2期	局部晚期乳腺癌	7	INT230-6 monotherapy	蓋製襯繭網憲蓋淵衊繭(範膚願遞繭廠鏇構築鹽) = 醖鏇餘鑰鬱廠廠遞選願夢膚獵獵範築鏇鏇範窪 (選鏇壓積憲鏇簾鹽糧獵 ) 更多	积极	2022-02-15